EUCTR2016-004792-50-DEActive, not recruitingPhase 1
Multi-centre, Double-blind, Randomised, Active- and Placebo-Controlled, Confirmatory Trial to Demonstrate Efficacy and Safety of Traumed® Gel in Patients having Acute Ankle Sprain - Traumed Trial
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 808
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1.Acute unilateral Grade 1 or Grade 2 sprain of the lateral ankle
- •2.= 18 years of age
- •3.Legally competent male or female outpatient
- •4.Injury occurred within previous 24 hours before first treatment expected
- •5.Signed Informed Consent
- •6.After 5 minutes of rest, pain on passive movement by investigator measured by Visual Analog Scale (VAS)>50 mm
- •7.Not pregnant (as proven by negative pregnancy test in case of women of childbearing potential before first study drug administration) or breast-feeding. Females of childbearing potential must agree to maintain highly effective birth control throughout the study (see all details in section 9.6). Such methods include:
- •oral, intravaginal, transdermal combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation,
- •oral, injectable, implantable hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (if received medical assessment of the surgical success), sexual abstinence (only if defined as refraining from heterosexual intercourse during the entire period of trial participation).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 750
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 58
Exclusion Criteria
- •1.Similar injury affecting the same joint within the past 6 months
- •2.Bilateral ankle injury
- •3.Grade 3 ankle sprain
- •4.Fracture of the ankle (It should be excluded by using e.g. the Ottawa Ankle Rules. In case of any doubt the exclusion of fracture by x-ray should be considered as per standard of care)
- •5.Chronic joint disorders such as clinically relevant osteoarthritis or aseptic arthritis
- •6.Disorders that may lead to joint oedema for other reasons than ankle sprain (such as heart failure, thrombosis, lymphedema and others)
- •7.Diagnosis requiring bed rest, hospitalization, surgery, or use of any cast during the planned treatment period
- •8.Debilitating acute or chronic illness
- •9.Use of systemic and/or topical corticosteroids in the previous 8 weeks, any analgesics (e.g. paracetamol/ acetaminophen) in the previous 24 hours before Screening Visit, or 48 hours in the case of long-acting non-steroidal anti-inflammatory drug (NSAID), cyclooxygenase type 2 (COX-2) specific inhibitors, or tramadol and other opioids. Low dose acetylsalicylic acid (70 – 100 mg per day) for anti-thrombotic therapy is permitted if doses are stable for the month prior to Screening Visit and planned to be stable during the entire study
- •10.History of sensitivity to any component of the study drugs (including e.g. paracetamol/ acetaminophen intolerance; patients in whom asthma attacks, skin rash or acute rhinitis are triggered by acetylsalicylic acid or non-steroidal anti-inflammatory drugs (NSAIDs)
- •11.Unwilling or unable to comply with all the requirements of the study protocol
- •12.Concurrent injury to proximal structures in ipsilateral lower extremity (i.e. concurrent shin, knee, thigh, or hip injury)
- •13.History of ligament avulsion, fracture or surgery to the affected lower extremity
- •14.Presence of infections and/or skin diseases in the area of the study treatment site (including psoriasis)
- •15.Any previous treatments of the injured ankle, whether topical or systematic, are prohibited except RICE (simultaneous combination of all 4 elements Rest, Ice, Compression and Elevation which is restricted to be used until starting treatment with the investigational drug).
- •16.Participation in any clinical study within the past 4 weeks
- •17.Any relationship of dependence with the sponsor or with the investigator
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study of ixekizumab (LY2439821) in participants from 6 to less than 18 years of age with moderate to severe plaque psoriasis.EUCTR2016-003331-38-NLEli Lilly and Company201
Active, not recruiting
Phase 1
A study of ixekizumab (LY2439821) in participants from 6 to less than 18 years of age with moderate to severe plaque psoriasis.EUCTR2016-003331-38-PLEli Lilly and Company201
Active, not recruiting
Phase 1
A study of ixekizumab (LY2439821) in participants from 6 to less than 18 years of age with moderate to severe plaque psoriasis.Moderate-to-Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2016-003331-38-DEEli Lilly and Company201
Active, not recruiting
Not Applicable
Trial to compare the efficacy and safety of tretinoin clindamycin phosphate gel to clindamycin phosphate gel alone, tretinoin gel alone, and vehicle in the treatment of acne vulgaris in patients from 12 to less than 18 years of age.Treatment of acne vulgarisMedDRA version: 14.1Level: HLTClassification code 10000497Term: AcnesSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-022918-15-Outside-EU/EEADow Pharmaceutical Sciences1,288
Recruiting
Unknown
Randomised, multicentre, controlled, double-blind, prospective study to evaluate the superiority of the Smoke Free App compared to standard therapy in dependent smokersF17Mental and behavioural disorders due to use of tobaccoDRKS00031140Smoke Free 23 GmbH1,442